Abstract
Functional inactivation of the retinoblastoma tumor suppressor gene product (RB) is a common event in human cancers. Classically, RB functions to constrain cellular proliferation, and loss of RB is proposed to facilitate the hyperplastic proliferation associated with tumorigenesis. To understand the repertoire of regulatory processes governed by RB, two models of RB loss were utilized to perform microarray analysis. In murine embryonic fibroblasts harboring germline loss of RB, there was a striking deregulation of gene expression, wherein distinct biological pathways were altered. Specifically, genes involved in cell cycle control and classically associated with E2F-dependent gene regulation were upregulated via RB loss. In contrast, a program of gene expression associated with immune function and response to pathogens was significantly downregulated with the loss of RB. To determine the specific influence of RB loss during a defined period and without the possibility of developmental compensation as occurs in embryonic fibroblasts, a second system was employed wherein Rb was acutely knocked out in adult fibroblasts. This model confirmed the distinct regulation of cell cycle and immune modulatory genes through RB loss. Analyses of cis-elements supported the hypothesis that the majority of those genes upregulated with RB loss are regulated via the E2F family of transcription factors. In contrast, those genes whose expression was reduced with the loss of RB harbored different promoter elements. Consistent with these analyses, we found that disruption of E2F-binding function of RB was associated with the upregulation of gene expression. In contrast, cells harboring an RB mutant protein (RB-750F) that retains E2F-binding activity, but is specifically deficient in the association with LXCXE-containing proteins, failed to upregulate these same target genes. However, downregulation of genes involved in immune function was readily observed with disruption of the LXCXE-binding function of RB. Thus, these studies demonstrate that RB plays a significant role in both the positive and negative regulations of transcriptional programs and indicate that loss of RB has distinct biological effects related to both cell cycle control and immune function.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Arany I, Tyring SK . (1996). Status of local cellular immunity in interferon-responsive and -nonresponsive human papillomavirus-associated lesions. Sex Transm Dis 23: 475–480.
Batsche E, Moschopoulos P, Desroches J, Bilodeau S, Drouin J . (2005). Retinoblastoma and the related pocket protein p107 act as coactivators of NeuroD1 to enhance gene transcription. J Biol Chem 280: 16088–16095.
Black EP, Huang E, Dressman H, Rempel R, Laakso N, Asa SL et al.(2003). Distinct gene expression phenotypes of cells lacking Rb and Rb family members. Cancer Res 63: 3716–3723.
Blais A, Dynlacht BD . (2004). Hitting their targets: an emerging picture of E2F and cell cycle control. Curr Opin Genet Dev 14: 527–532.
Brehm A, Miska EA, McCance DJ, Reid JL, Bannister AJ, Kouzarides T . (1998). Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 391: 597–601.
Cam H, Balciunaite E, Blais A, Spektor A, Scarpulla RC, Young R et al. (2004). A common set of gene regulatory networks links metabolism and growth inhibition. Mol Cell 16: 399–411.
Cam H, Dynlacht BD . (2003). Emerging roles for E2F: beyond the G1/S transition and DNA replication. Cancer Cell 3: 311–316.
Chen TT, Wang JY . (2000). Establishment of irreversible growth arrest in myogenic differentiation requires the RB LXCXE-binding function. Mol Cell Biol 20: 5571–5580.
Cobrinik D . (2005). Pocket proteins and cell cycle control. Oncogene 24: 2796–2809.
Dimova DK, Dyson NJ . (2005). The E2F transcriptional network: old acquaintances with new faces. Oncogene 24: 2810–2826.
Eason DD, Coppola D, Livingston S, Shepherd AT, Blanck G . (2001). Loss of MHC class II inducibility in hyperplastic tissue in Rb-defective mice. Cancer Lett 171: 209–214.
Frolov MV, Dyson NJ . (2004). Molecular mechanisms of E2F-dependent activation and pRB-mediated repression. J Cell Sci 117 (Part 11): 2173–2181.
Iavarone A, King ER, Dai XM, Leone G, Stanley ER, Lasorella A . (2004). Retinoblastoma promotes definitive erythropoiesis by repressing Id2 in fetal liver macrophages. Nature 432: 1040–1045.
Iovino F, Lentini L, Amato A, Di Leonardo A . (2006). RB acute loss induces centrosome amplification and aneuploidy in murine primary fibroblasts. Mol Cancer 20: 5:38.
Ishida S, Huang E, Zuzan H, Spang R, Leone G, West M et al. (2001). Role for E2F in control of both DNA replication and mitotic functions as revealed from DNA microarray analysis. Mol Cell Biol 21: 4684–4699.
Jegga AG, Gupta A, Gowrisankar S, Deshmukh MA, Connolly S, Finley K et al. (2005). CisMols Analyzer: identification of compositionally similar cis-element clusters in ortholog conserved regions of coordinately expressed genes. Nucleic Acids Res 33: W408–W411.
Jegga AG, Sherwood SP, Carman JW, Pinski AT, Phillips JL, Pestian JP et al. (2002). Detection and visualization of compositionally similar cis-regulatory element clusters in orthologous and coordinately controlled genes. Genome Res 12: 1408–1417.
Knudsen ES, Buckmaster C, Chen TT, Feramisco JR, Wang JY . (1998). Inhibition of DNA synthesis by RB: effects on G1/S transition and S-phase progression. Genes Dev 12: 2278–2292.
Kouzarides T . (1995). Transcriptional control by the retinoblastoma protein. Semin Cancer Biol 6: 91–98.
Le Buanec H, D'Anna R, Lachgar A, Zagury JF, Bernard J, Ittele D et al. (1999). HPV-16 E7 but not E6 oncogenic protein triggers both cellular immunosuppression and angiogenic processes. Biomed Pharmacother 53: 424–431.
Lu Y, Ussery GD, Muncaster MM, Gallie BL, Blanck G . (1994). Evidence for retinoblastoma protein (RB) dependent and independent IFN-gamma responses: RB coordinately rescues IFN-gamma induction of MHC class II gene transcription in noninducible breast carcinoma cells. Oncogene 9: 1015–1019.
Markey MP, Angus SP, Strobeck MW, Williams SL, Gunawardena RW, Aronow BJ et al. (2002). Unbiased analysis of RB-mediated transcriptional repression identifies novel targets and distinctions from E2F action. Cancer Res 62: 6587–6597.
Mayhew CN, Perkin LM, Zhang X, Sage J, Jacks T, Knudsen ES . (2004). Discrete signaling pathways participate in RB-dependent responses to chemotherapeutic agents. Oncogene 23: 4107–4120.
Morris EJ, Dyson NJ . (2001). Retinoblastoma protein partners. Adv Cancer Res 82: 1–54.
Nevins JR . (2001). The Rb/E2F pathway and cancer. Hum Mol Genet 10: 699–703.
Osborne A, Tschickardt M, Blanck G . (1997). Retinoblastoma protein expression facilitates chromatin remodeling at the HLA-DRA promoter. Nucleic Acids Res 25: 5095–5102.
Osborne AR, Zhang H, Fejer G, Palubin KM, Niesen MI, Blanck G . (2004). Oct-1 maintains an intermediate, stable state of HLA-DRA promoter repression in Rb-defective cells: an Oct-1-containing repressosome that prevents NF-Y binding to the HLA-DRA promoter. J Biol Chem 279: 28911–28919.
Qin XQ, Livingston DM, Ewen M, Sellers WR, Arany Z, Kaelin Jr WG . (1995). The transcription factor E2F-1 is a downstream target of RB action. Mol Cell Biol 15: 742–755.
Ren B, Cam H, Takahashi Y, Volkert T, Terragni J, Young RA et al. (2002). E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. Genes Dev 16: 245–256.
Sage J, Miller AL, Perez-Mancera PA, Wysocki JM, Jacks T . (2003). Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature 424: 223–228.
Sherr CJ, McCormick F . (2002). The RB and p53 pathways in cancer. Cancer Cell 2: 103–112.
Strobeck MW, Knudsen KE, Fribourg AF, DeCristofaro MF, Weissman BE, Imbalzano AN et al. (2000). BRG-1 is required for RB-mediated cell cycle arrest. Proc Natl Acad Sci USA 97: 7748–7753.
Thomas DM, Carty SA, Piscopo DM, Lee JS, Wang WF, Forrester WC et al. (2001). The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation. Mol Cell 8: 303–316.
Thomas DM, Yang HS, Alexander K, Hinds PW . (2003). Role of the retinoblastoma protein in differentiation and senescence. Cancer Biol Ther 2: 124–130.
Trouche D, Le Chalony C, Muchardt C, Yaniv M, Kouzarides T . (1997). RB and hbrm cooperate to repress the activation functions of E2F1. Proc Natl Acad Sci USA 94: 11268–11273.
Vernell R, Helin K, Muller H . (2003). Identification of target genes of the p16INK4A–pRB–E2F pathway. J Biol Chem 278: 46124–46137.
Wang JY, Knudsen ES, Welch PJ . (1994). The retinoblastoma tumor suppressor protein. Adv Cancer Res 64: 25–28 5..
Welch PJ, Wang JY . (1995). Abrogation of retinoblastoma protein function by c-Abl through tyrosine kinase-dependent and -independent mechanisms. Mol Cell Biol 15: 5542–5551.
Xin H, Pramanik R, Choubey D . (2003). Retinoblastoma (Rb) protein upregulates expression of the Ifi202 gene encoding an interferon-inducible negative regulator of cell growth. Oncogene 22: 4775–4785.
Zhu X, Pattenden S, Bremner R . (1999). pRB is required for interferon-gamma-induction of the MHC class II abeta gene. Oncogene 18: 4940–4947.
Acknowledgements
We are grateful to Dr George Blanck, Dr Karen Knudsen and Dr Lisa Morey for critical commentary on the manuscript. We also thank Dr Julien Sage and Dr Tyler Jacks for the provision of mouse strains.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).
Supplementary information
Rights and permissions
About this article
Cite this article
Markey, M., Bergseid, J., Bosco, E. et al. Loss of the retinoblastoma tumor suppressor: differential action on transcriptional programs related to cell cycle control and immune function. Oncogene 26, 6307–6318 (2007). https://doi.org/10.1038/sj.onc.1210450
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1210450
Keywords
This article is cited by
-
Analysis of Polymorphisms in the Mediator Complex Subunit 13-like (Med13L) Gene in the Context of Immune Function and Development of Experimental Arthritis
Archivum Immunologiae et Therapiae Experimentalis (2018)
-
Multiple molecular interactions redundantly contribute to RB-mediated cell cycle control
Cell Division (2017)
-
A distinct function of the retinoblastoma protein in the control of lipid composition identified by lipidomic profiling
Oncogenesis (2017)
-
Emerging roles of p53 and other tumour-suppressor genes in immune regulation
Nature Reviews Immunology (2016)
-
Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer
Nature Reviews Urology (2011)